COSENTYX targets and blocks IL-17A, an important molecule that contributes to inflammation that may lead to HS symptoms. See how COSENTYX takes on HS—from the inside out.

Sep 4, 2025 · Cosentyx has demonstrated clinically meaningful benefits for many adults with moderate to severe hidradenitis suppurativa, helping to reduce painful symptoms and improve daily life.

Review the flexible maintenance dosing and administration options for COSENTYX as a treatment option for Hidradenitis Suppurativa. See full Prescribing and Safety Info.

Basel, October 31, 2023 — Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved Cosentyx ® …

1.6 Hidradenitis Suppurativa COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS).

The U.S. Food and Drug Administration (FDA) recently announced the approval of Cosentyx (secukinumab), developed by Novartis, for the treatment of moderate to severe hidradenitis …

Nov 1, 2023 · Cosentyx ® (secukinumab) from Novartis is now approved to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that …

Cosentyx is a genetically engineered antibody, or a protein the immune system uses to identify and neutralize substances. Cosentyx is believed to work by inhibiting interleukin 17A, a chemical …

The recommended dose of COSENTYX for adults with moderate to severe hidradenitis suppurativa is 300 mg.‡ To start, your doctor may prescribe 5 weekly loading doses.

May be effective for HS at dosage of 100 mg daily; however, dose-ranging studies are needed to determine optimal dosage.